We further cocultured APG-2575-treated tumor cells with BCL-2 knockdown or overexpression with IL-4-activated macrophages and measured the protein levels of p-NF-κB p65 and NLRP3 in IL-4-activated macrophages, and we obtained consistent results (Supplementary Fig. S10L–M, Q–R), indicating that genetic alteration of BCL-2 expression in cancer cells also had no impact on APG-2575-mediated activation of NF-κB/NLRP3 signaling. The gene discussed is BCL2; the disease is cancer.